JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $7
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $10 to $7.
Last updated: 2026-11-17 04:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Recursion Pharmaceuticals, Inc. (RXRX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.91, with a market capitalization of $1.99B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.77 to $5.24. This page covers its latest market performance, valuation, price trends and company information.
$1.99B | |
$3.10 | |
$3.17 | |
$2.88 | |
$3.19 | |
18.41M | |
23.38M | |
-- | |
$5.24 | |
$2.77 | |
-- | |
-- |
Recursion Pharmaceuticals, Inc. (RXRX) last closed at $2.91 as of 2026-11-17 01:00:00, down 8.95% ($0.29) from the previous close of $3.19.
During the latest regular trading session, RXRX traded between $2.88 and $3.17, with a volume of 18.41M shares. The closing price was near the lower end and near the lower end of its 52-week range.
RXRX is up 0.20% as of the last close.
Over the past seven days, Recursion Pharmaceuticals, Inc. (RXRX) moved from $3.50 to $2.91, representing a decline of 17.00% ($0.60).
The stock traded between $2.88 and $3.87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 19.19 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.5%
RXRX is currently trading at $2.91, placing it 5.5% of the way from its 52-week low of $2.77 to its 52-week high of $5.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 600 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Recursion Pharmaceuticals, Inc. and RXRX stock.
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $10 to $7.
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.
DaltonTx announced the appointment of Melissa Landon, Ph.D., as Chief Commercial Officer to lead commercial strategy and expand adoption of its Dalton platform across pharma, biotech, and CRO partners. Landon brings 20+ years of AI/ML experience in drug discovery, most recently from Merck KGaA/MilliporeSigma, and previously served as Chief Strategy Officer at Cyclica.
Eligible investors can buy real shares of Recursion Pharmaceuticals, Inc. (RXRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RXRX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RXRX shares and USD.
RXRX Shares to USD
1.00 RXRX shares = 2.905 USD
Calculations are estimates based on the latest available price and are for reference only.